The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
Madrid, 21 March 2023 Laboratorios Farmacéuticos ROVI announces its incorporation as a member of the General Assembly of the Spanish...
3 min
21/03/2023
ROVI REPORTS OPERATING REVENUE GROWTH OF 26% AND EBITDA GROWTH OF 37% Operating revenue increased by 26% to 817.7 million euros...
3 min
21/02/2023
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023